- Home
- GMED vs ROIV Comparison
GMED vs ROIV Comparison
Compare GMED & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMED
- ROIV
- Stock Information
- Founded
- GMED 2003
- ROIV 2014
- Country
- GMED United States
- ROIV United Kingdom
- Employees
- GMED N/A
- ROIV N/A
- Industry
- GMED Medical/Dental Instruments
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- GMED Health Care
- ROIV Health Care
- Exchange
- GMED Nasdaq
- ROIV Nasdaq
- Market Cap
- GMED 8.1B
- ROIV 7.8B
- IPO Year
- GMED 2012
- ROIV N/A
- Fundamental
- Price
- GMED $55.86
- ROIV $11.36
- Analyst Decision
- GMED Buy
- ROIV Buy
- Analyst Count
- GMED 13
- ROIV 4
- Target Price
- GMED $91.10
- ROIV $17.50
- AVG Volume (30 Days)
- GMED 1.5M
- ROIV 7.8M
- Earning Date
- GMED 08-05-2025
- ROIV 08-07-2025
- Dividend Yield
- GMED N/A
- ROIV N/A
- EPS Growth
- GMED 145.70
- ROIV N/A
- EPS
- GMED 1.34
- ROIV N/A
- Revenue
- GMED $2,510,810,000.00
- ROIV $29,053,000.00
- Revenue This Year
- GMED $15.47
- ROIV $3.28
- Revenue Next Year
- GMED $8.53
- ROIV $156.84
- P/E Ratio
- GMED $42.95
- ROIV N/A
- Revenue Growth
- GMED 32.26
- ROIV N/A
- 52 Week Low
- GMED $54.48
- ROIV $8.73
- 52 Week High
- GMED $94.93
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- GMED 37.27
- ROIV 52.70
- Support Level
- GMED $56.64
- ROIV $10.71
- Resistance Level
- GMED $58.14
- ROIV $11.58
- Average True Range (ATR)
- GMED 1.54
- ROIV 0.31
- MACD
- GMED -0.04
- ROIV 0.02
- Stochastic Oscillator
- GMED 6.06
- ROIV 60.93
About GMED Globus Medical Inc.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.